Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 4,191

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children

Open access
Liu, Catherine, Bayer, Arnold, Cosgrove, Sara E., Daum, Robert S., Fridkin, Scott K., Gorwitz, Rachel J., Kaplan, Sheldon L., Karchmer, Adolf W., Levine, Donald P., Murray, Barbara E., Rybak, Michael J., Talan, David A., Chambers, Henry F.·2011·Clinical Infectious Diseases
DOI 10.1093/cid/ciq146
Open this paper in CoChat — free account

Abstract

Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). The guidelines are intended for use by health care providers who care for adult and pediatric patients with MRSA infections. The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections. Recommendations are provided regarding vancomycin dosing and monitoring, management of infections due to MRSA strains with reduced susceptibility to vancomycin, and vancomycin treatment failures.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciq146

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 349

  1. Calfee, 2008, Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals, Infect Control Hosp Epidemiol, 29, S62, 10.1086/591061 · DOI · Paper page
  2. Anderson, 2008, Strategies to prevent surgical site infections in acute care hospitals, Infect Control Hosp Epidemiol, 29, S51, 10.1086/591064 · DOI · Paper page
  3. Rybak, 2009, Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists, Clin Infect Dis, 49, 325, 10.1086/600877 · DOI · Paper page
  4. Herold, 1998, Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk, JAMA, 279, 593, 10.1001/jama.279.8.593 · DOI · Paper page
  5. D'Agata, 2009, Modeling the invasion of community-acquired methicillin-resistant Staphylococcus aureus into hospitals, Clin Infect Dis, 48, 274, 10.1086/595844 · DOI · Paper page
  6. Purcell, 2006, Economic impact of the community-acquired methicillin-resistant Staphylococcus aureus epidemic on the Driscoll Children's Health Plan, Pediatr Infect Dis J, 25, 178, 10.1097/01.inf.0000199304.68890.60 · DOI · Paper page
  7. Noskin, 2005, The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database, Arch Intern Med, 165, 1756, 10.1001/archinte.165.15.1756 · DOI · Paper page
  8. Lee, 2007, Incidence and clinical characteristics of methicillin-resistant Staphylococcus aureus necrotizing fasciitis in a large urban hospital, Am J Surg, 194, 809, 10.1016/j.amjsurg.2007.08.047 · DOI
  9. Pannaraj, 2006, Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection, Clin Infect Dis, 43, 953, 10.1086/507637 · DOI
  10. Wright, 2008, Pediatric mediastinitis as a complication of methicillin-resistant Staphylococcus aureus retropharyngeal abscess, Arch Otolaryngol Head Neck Surg, 134, 408, 10.1001/archotol.134.4.408 · DOI
  11. Gonzalez, 2006, Venous thrombosis associated with staphylococcal osteomyelitis in children, Pediatrics, 117, 1673, 10.1542/peds.2005-2009 · DOI
  12. Francis, 2005, Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes, Clin Infect Dis, 40, 100, 10.1086/427148 · DOI · Paper page
  13. Hageman, 2006, Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season, Emerg Infect Dis, 12, 894, 10.3201/eid1206.051141 · DOI · Paper page
  14. Centers for Disease Control and Prevention, 2007, Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza–Louisiana Georgia, December 2006-January 2007, MMWR Morb Mortal Wkly Rep, 56, 325
  15. Gonzalez, 2005, Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection, Clin Infect Dis, 41, 583, 10.1086/432475 · DOI · Paper page
  16. Arnold, 2006, Changing patterns of acute hematogenous osteomyelitis and septic arthritis: emergence of community-associated methicillin-resistant Staphylococcus aureus, J Pediatr Orthop, 26, 703, 10.1097/01.bpo.0000242431.91489.b4 · DOI · Paper page
  17. Crary, 2006, Venous thrombosis and thromboembolism in children with osteomyelitis, J Pediatr, 149, 537, 10.1016/j.jpeds.2006.06.067 · DOI
  18. Rutar, 2006, Ophthalmic manifestations of infections caused by the USA300 clone of community-associated methicillin-resistant Staphylococcus aureus, Ophthalmology, 113, 1455, 10.1016/j.ophtha.2006.03.031 · DOI
  19. Kravitz, 2005, Purpura fulminans due to Staphylococcus aureus, Clin Infect Dis, 40, 941, 10.1086/428573 · DOI · Paper page
  20. Adem, 2005, Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children, N Engl J Med, 353, 1245, 10.1056/NEJMoa044194 · DOI · Paper page
  21. Field, 1990, Institute of Medicine Committee to Advise the Public Health Service on clinical practice guidelines, clinical practice guidelines: directions for a new program, 52, 10.17226/1626 · DOI · Paper page
  22. 1979, Canadian Task Force on the Periodic Health Examination, Can Med Assoc J, 121, 1193
  23. Martinez-Aguilar, 2003, Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children, Pediatr Infect Dis J, 22, 593, 10.1097/01.inf.0000073163.37519.ee · DOI · Paper page
  24. Frank, 2002, Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children, Pediatr Infect Dis J, 21, 530, 10.1097/00006454-200206000-00010 · DOI · Paper page
  25. Marcinak, 2003, Treatment of community-acquired methicillin-resistant Staphylococcus aureus in children, Curr Opin Infect Dis, 16, 265, 10.1097/00001432-200306000-00014 · DOI
  26. Nicholas, 1975, Concentration of clindamycin in human bone, Antimicrob Agents Chemother, 8, 220, 10.1128/AAC.8.2.220 · doi:10.1128/aac.8.2.220
  27. Joiner, 1981, Antibiotic levels in infected and sterile subcutaneous abscesses in mice, J Infect Dis, 143, 487, 10.1093/infdis/143.3.487 · doi:10.1093/infdis/143.3.487
  28. Panzer, 1972, Clindamycin levels in various body tissues and fluids, J Clin Pharmacol New Drugs, 12, 259, 10.1002/j.1552-4604.1972.tb00052.x · doi:10.1002/j.1552-4604.1972.tb00052.x
  29. Tsuji, 2007, Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents, Diagn Microbiol Infect Dis, 58, 41, 10.1016/j.diagmicrobio.2006.10.021 · DOI
  30. Hulten, 2006, Three-year surveillance of community onset health care-associated Staphylococcus aureus infections in children, Pediatr Infect Dis J, 25, 349, 10.1097/01.inf.0000207404.50143.1e · DOI
  31. Lewis, 2005, Inducible clindamycin resistance in Staphylococci: should clinicians microbiologists be concerned?, Clin Infect Dis, 40, 280, 10.1086/426894 · DOI · Paper page
  32. Raveh, 2006, Risk factors for Clostridium difficile toxin-positive nosocomial diarrhoea, Int J Antimicrob Agents, 28, 231, 10.1016/j.ijantimicag.2006.04.013 · doi:10.1016/j.ijantimicag.2006.04.013
  33. Steele, 2006, Adherence issues related to the selection of antistaphylococcal or antifungal antibiotic suspensions for children, Clin Pediatr (Phila), 45, 245, 10.1177/000992280604500306 · DOI
  34. Nahum, 2006, Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks, Obstet Gynecol, 107, 1120, 10.1097/01.AOG.0000216197.26783.b5 · DOI · Paper page
  35. Marty, 2006, Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis, J Clin Microbiol, 44, 595, 10.1128/JCM.44.2.595-597.2006 · DOI
  36. Vikram, 2005, Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin, J Clin Microbiol, 43, 5384, 10.1128/JCM.43.10.5384-5387.2005 · DOI
  37. Hayden, 2005, Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus, J Clin Microbiol, 43, 5285, 10.1128/JCM.43.10.5285-5287.2005 · DOI · Paper page
  38. Boucher, 2007, Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus, Clin Infect Dis, 45, 601, 10.1086/520655 · DOI
  39. Friedman, 2006, Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus, Antimicrob Agents Chemother, 50, 2137, 10.1128/AAC.00039-06 · DOI · Paper page
  40. Sakoulas, 2006, Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin, Antimicrob Agents Chemother, 50, 1581, 10.1128/AAC.50.4.1581-1585.2006 · DOI · Paper page
  41. Patel, 2006, An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus, Clin Infect Dis, 42, 1652, 10.1086/504084 · DOI
  42. Fowler, 2006, Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus, N Engl J Med, 355, 653, 10.1056/NEJMoa053783 · DOI · Paper page
  43. Arbeit, 2004, The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections, Clin Infect Dis, 38, 1673, 10.1086/420818 · DOI · Paper page
  44. Miller, 2010, Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases, Clin Infect Dis, 50, e63, 10.1086/652656 · doi:10.1086/652656
  45. Abdel-Rahman, 2008, Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections, Pediatr Infect Dis J, 27, 330, 10.1097/INF.0b013e318160edfc · doi:10.1097/inf.0b013e318160edfc
  46. Howe, 2003, Activity of AZD2563, a novel oxazolidinone, against Staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid, Antimicrob Agents Chemother, 47, 3651, 10.1128/AAC.47.11.3651-3652.2003 · DOI
  47. Wootton, 2002, In vitro activity of 21 antimicrobials against vancomycin-resistant Staphylococcus aureus (VRSA) and heteroVRSA (hVRSA), J Antimicrob Chemother, 50, 760, 10.1093/jac/dkf184 · DOI
  48. Bozdogan, 2003, Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center, J Antimicrob Chemother, 52, 864, 10.1093/jac/dkg457 · DOI
  49. Sanchez Garcia, 2010, Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit, JAMA, 303, 2260, 10.1001/jama.2010.757 · DOI · Paper page
  50. Pillai, 2002, Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype, J Infect Dis, 186, 1603, 10.1086/345368 · DOI
  51. Arias, 2008, Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase, J Clin Microbiol, 46, 892, 10.1128/JCM.01886-07 · DOI
  52. Toh, 2007, Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid, Mol Microbiol, 64, 1506, 10.1111/j.1365-2958.2007.05744.x · DOI · Paper page
  53. Bressler, 2004, Peripheral neuropathy associated with prolonged use of linezolid, Lancet Infect Dis, 4, 528, 10.1016/S1473-3099(04)01109-0 · DOI · Paper page
  54. Wigen, 2002, Serotonin syndrome and linezolid, Clin Infect Dis, 34, 1651, 10.1086/340710 · DOI
  55. Meissner, 2003, Hematologic effects of linezolid in young children, Pediatr Infect Dis J, 22, S186, 10.1097/01.inf.0000087021.20838.d9 · DOI
  56. Saiman, 2003, Safety and tolerability of linezolid in children, Pediatr Infect Dis J, 22, S193, 10.1097/01.inf.0000087022.58089.d8 · DOI
  57. Drew, 2000, Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy, J Antimicrob Chemother, 46, 775, 10.1093/jac/46.5.775 · DOI
  58. Sander, 2002, Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci, Intensive Care Med, 28, 1157, 10.1007/s00134-002-1358-7 · DOI · Paper page
  59. Loeffler, 2002, Safety and efficacy of quinupristin/dalfopristin for treatment of invasive gram-positive infections in pediatric patients, Pediatr Infect Dis J, 21, 950, 10.1097/00006454-200210000-00013 · doi:10.1097/00006454-200210000-00013
  60. Blaser, 1995, In vivo verification of in vitro model of antibiotic treatment of device-related infection, Antimicrob Agents Chemother, 39, 1134, 10.1128/AAC.39.5.1134 · DOI
  61. Widmer, 1990, Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections, J Infect Dis, 162, 96, 10.1093/infdis/162.1.96 · DOI · Paper page
  62. Zimmerli, 1994, Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus, J Antimicrob Chemother, 33, 959, 10.1093/jac/33.5.959 · DOI · Paper page
  63. Nau, 1992, Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges, J Antimicrob Chemother, 29, 719, 10.1093/jac/29.6.719 · DOI
  64. Euba, 2009, Pilot study of ampicillin-ceftriaxone combination for treatment of orthopedic infections due to Enterococcus faecalis, Antimicrob Agents Chemother, 53, 4305, 10.1128/AAC.00444-09 · DOI
  65. Zimmerli, 1998, Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group, JAMA, 279, 1537, 10.1001/jama.279.19.1537 · DOI · Paper page
  66. Norden, 1986, Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy, South Med J, 79, 947, 10.1097/00007611-198608000-00008 · doi:10.1097/00007611-198608000-00008
  67. Baddour, 2005, Infective endocarditis: diagnosis, antimicrobial therapy, management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America, Circulation, 111, e394
  68. Saravolatz, 2009, Telavancin: a novel lipoglycopeptide, Clin Infect Dis, 49, 1908, 10.1086/648438 · doi:10.1086/648438
  69. Ruhe, 2005, Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature, Clin Infect Dis, 40, 1429, 10.1086/429628 · DOI
  70. Tenover, 2006, Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States, J Clin Microbiol, 44, 108, 10.1128/JCM.44.1.108-118.2006 · DOI · Paper page
  71. Bismuth, 1990, Gene heterogeneity for tetracycline resistance in Staphylococcus spp, Antimicrob Agents Chemother, 34, 1611, 10.1128/AAC.34.8.1611 · DOI
  72. Schwartz, 2009, Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300, Clin Infect Dis, 48, 1483, 10.1086/598510 · DOI
  73. Rodvold, 2006, Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose, J Antimicrob Chemother, 58, 1221, 10.1093/jac/dkl403 · DOI · Paper page
  74. Naimi, 2003, Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection, JAMA, 290, 2976, 10.1001/jama.290.22.2976 · DOI · Paper page
  75. Cenizal, 2007, Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 51, 2628, 10.1128/AAC.00206-07 · DOI
  76. Szumowski, 2007, Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic, Antimicrob Agents Chemother, 51, 423, 10.1128/AAC.01244-06 · DOI
  77. Euba, 2009, Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis, Antimicrob Agents Chemother, 53, 2672, 10.1128/AAC.01504-08 · doi:10.1128/aac.01504-08
  78. Sanchez, 1997, Cotrimoxazole plus rifampicin in the treatment of staphylococcal osteoarticular infection, Enferm Infecc Microbiol Clin, 15, 10
  79. Stein, 1998, Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole), Antimicrob Agents Chemother, 42, 3086, 10.1128/AAC.42.12.3086 · DOI
  80. Adra, 2004, Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections, Ann Pharmacother, 38, 338, 10.1345/aph.1D156 · DOI
  81. Markowitz, 1992, Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection, Ann Intern Med, 117, 390, 10.7326/0003-4819-117-5-390 · DOI · Paper page
  82. Hyun, 2009, Trimethoprim-sulfamethoxazole or clindamycin for treatment of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections, Pediatr Infect Dis J, 28, 57, 10.1097/INF.0b013e3181826e5e · DOI
  83. Antoniou, 2010, Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study, Arch Intern Med, 170, 1045, 10.1001/archinternmed.2010.142 · DOI
  84. Deresinski, 2007, Counterpoint: vancomycin Staphylococcus aureus–an antibiotic enters obsolescence, Clin Infect Dis, 44, 1543, 10.1086/518452 · DOI · Paper page
  85. Kollef, 2007, Limitations of vancomycin in the management of resistant staphylococcal infections, Clin Infect Dis, 45, S191, 10.1086/519470 · DOI · Paper page
  86. Sakoulas, 2004, Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia, J Clin Microbiol, 42, 2398, 10.1128/JCM.42.6.2398-2402.2004 · DOI · Paper page
  87. LaPlante, 2004, Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model, Antimicrob Agents Chemother, 48, 4665, 10.1128/AAC.48.12.4665-4672.2004 · DOI · Paper page
  88. Small, 1990, Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users, Antimicrob Agents Chemother, 34, 1227, 10.1128/AAC.34.6.1227 · DOI · Paper page
  89. Stryjewski, 2007, Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia, Clin Infect Dis, 44, 190, 10.1086/510386 · DOI · Paper page
  90. Chang, 2003, Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study, Medicine (Baltimore), 82, 333, 10.1097/01.md.0000091184.93122.09 · DOI · Paper page
  91. Kim, 2008, Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia, Antimicrob Agents Chemother, 52, 192, 10.1128/AAC.00700-07 · DOI · Paper page
  92. Lodise, 2007, Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus, Antimicrob Agents Chemother, 51, 3731, 10.1128/AAC.00101-07 · DOI
  93. Graziani, 1988, Vancomycin concentrations in infected and noninfected human bone, Antimicrob Agents Chemother, 32, 1320, 10.1128/AAC.32.9.1320 · DOI
  94. Lamer, 1993, Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients, Antimicrob Agents Chemother, 37, 281, 10.1128/AAC.37.2.281 · DOI · Paper page
  95. Cooper, 1986, Pharmacokinetics of vancomycin. Vancomycin: a comprehensive review of 30 years clinical experience, 23
  96. Albanese, 2000, Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit, Antimicrob Agents Chemother, 44, 1356, 10.1128/AAC.44.5.1356-1358.2000 · DOI
  97. Pallin, 2008, Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus, Ann Emerg Med, 51, 291, 10.1016/j.annemergmed.2007.12.004 · DOI · Paper page
  98. Edelsberg, 2009, Trends in US hospital admissions for skin and soft tissue infections, Emerg Infect Dis, 15, 1516, 10.3201/eid1509.081228 · DOI · Paper page
  99. Fitch, 2007, Videos in clinical medicine. Abscess incision and drainage, N Engl J Med, 357, e20, 10.1056/NEJMvcm071319 · DOI
  100. Stevens, 2005, Practice guidelines for the diagnosis and management of skin and soft-tissue infections, Clin Infect Dis, 41, 1373, 10.1086/497143 · DOI · Paper page
  101. Lee, 2004, Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus, Pediatr Infect Dis J, 23, 123, 10.1097/01.inf.0000109288.06912.21 · DOI · Paper page
  102. Schmitz, 2010, Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection, Ann Emerg Med, 56, 283, 10.1016/j.annemergmed.2010.03.002 · DOI
  103. Duong, 2010, Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient, Ann Emerg Med, 55, 401, 10.1016/j.annemergmed.2009.03.014 · DOI · Paper page
  104. Ruhe, 2007, Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome, Clin Infect Dis, 44, 777, 10.1086/511872 · DOI
  105. Deleo, 2010, Community-associated meticillin-resistant Staphylococcus aureus, Lancet, 375, 1557, 10.1016/S0140-6736(09)61999-1 · DOI · Paper page
  106. Ruhe, 2007, Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 51, 3298, 10.1128/AAC.00262-07 · DOI
  107. Purcell, 2005, Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children's Hospital, Arch Pediatr Adolesc Med, 159, 980, 10.1001/archpedi.159.10.980 · DOI · Paper page
  108. Moellering, 2003, Linezolid: the first oxazolidinone antimicrobial, Ann Intern Med, 138, 135, 10.7326/0003-4819-138-2-200301210-00015 · DOI · Paper page
  109. Perlroth, 2008, Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature, Arch Intern Med, 168, 805, 10.1001/archinte.168.8.805 · DOI · Paper page
  110. d'Oliveira, 2003, Antimicrobial susceptibility and survey of macrolide resistance mechanisms among Streptococcus pyogenes isolated in Rio de Janeiro, Brazil, Microb Drug Resist, 9, 87, 10.1089/107662903764736382 · doi:10.1089/107662903764736382
  111. Libertin, 1983, Effects of trimethoprim-sulfamethoxazole and incubation atmosphere on isolation of group A streptococci, J Clin Microbiol, 18, 680, 10.1128/JCM.18.3.680-682.1983 · doi:10.1128/jcm.18.3.680-682.1983
  112. Trickett, 1973, Clinical experience: respiratory tract. Trimethoprim-sulfamethoxazole versus penicillin G in the treatment of group A beta-hemolytic streptococcal pharyngitis tonsillitis, J Infect Dis, 128, 693, 10.1093/infdis/128.Supplement_3.S693 · doi:10.1093/infdis/128.supplement_3.s693
  113. Han, 2007, High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center, J Clin Microbiol, 45, 1350, 10.1128/JCM.02274-06 · DOI
  114. Kaplan, 2005, Three-year surveillance of community-acquired Staphylococcus aureus infections in children, Clin Infect Dis, 40, 1785, 10.1086/430312 · DOI · Paper page
  115. Tayal, 2006, The effect of soft-tissue ultrasound on the management of cellulitis in the emergency department, Acad Emerg Med, 13, 384, 10.1197/j.aem.2005.11.074 · doi:10.1197/j.aem.2005.11.074
  116. Squire, 2005, ABSCESS: applied bedside sonography for convenient evaluation of superficial soft tissue infections, Acad Emerg Med, 12, 601, 10.1197/j.aem.2005.01.016 · doi:10.1197/j.aem.2005.01.016
  117. Epperly, 1986, The value of needle aspiration in the management of cellulitis, J Fam Pract, 23, 337
  118. Fleisher, 1980, Cellulitis: a prospective study, Ann Emerg Med, 9, 246, 10.1016/S0196-0644(80)80380-5 · doi:10.1016/s0196-0644(80)80380-5
  119. Fleisher, 1980, Cellulitis: bacterial etiology, clinical features, and laboratory findings, J Pediatr, 97, 591, 10.1016/S0022-3476(80)80014-X · doi:10.1016/s0022-3476(80)80014-x
  120. Lee, 1985, Fine-needle aspiration biopsy in diagnosis of soft tissue infections, J Clin Microbiol, 22, 80, 10.1128/JCM.22.1.80-83.1985 · DOI
  121. Newell, 1988, Value of needle aspiration in bacteriologic diagnosis of cellulitis in adults, J Clin Microbiol, 26, 401, 10.1128/JCM.26.3.401-404.1988 · doi:10.1128/jcm.26.3.401-404.1988
  122. Swartz, 2004, Clinical practice, Cellulitis N Engl J Med, 350, 904, 10.1056/NEJMcp031807 · DOI · Paper page
  123. Elliott, 2009, Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus, Pediatrics, 123, e959, 10.1542/peds.2008-2428 · DOI
  124. Jeng, 2010, The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation, Medicine (Baltimore), 89, 217, 10.1097/MD.0b013e3181e8d635 · DOI
  125. Weigelt, 2005, Linezolid versus vancomycin in treatment of complicated skin soft tissue infections, Antimicrob Agents Chemother, 49, 2260, 10.1128/AAC.49.6.2260-2266.2005 · DOI · Paper page
  126. Ellis-Grosse, 2005, The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam, Clin Infect Dis, 41, S341, 10.1086/431675 · DOI · Paper page
  127. Stryjewski, 2008, Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms, Clin Infect Dis, 46, 1683, 10.1086/587896 · DOI · Paper page
  128. Yogev, 2003, Linezolid for the treatment of complicated skin and skin structure infections in children, Pediatr Infect Dis J, 22, S172, 10.1097/01.inf.0000088671.35064.7c · DOI
  129. Hepburn, 2004, Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis, Arch Intern Med, 164, 1669, 10.1001/archinte.164.15.1669 · DOI · Paper page
  130. Miller, 2008, Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection, Clin Infect Dis, 46, 752, 10.1086/526773 · DOI · Paper page
  131. Centers for Disease Control Prevention, Environmental cleaning & disinfecting for MRSA: what's the difference between cleaners, sanitizers, and disinfectants? 2010
  132. Robicsek, 2009, Topical therapy for methicillin-resistant Staphylococcus aureus colonization: impact on infection risk, Infect Control Hosp Epidemiol, 30, 623, 10.1086/597550 · DOI
  133. Laupland, 2003, Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review, Clin Infect Dis, 37, 933, 10.1086/377735 · DOI · Paper page
  134. van Rijen, 2008, Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers, Cochrane Database Syst Rev, 4
  135. Wertheim, 2004, Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients: a randomized study, Ann Intern Med, 140, 419, 10.7326/0003-4819-140-6-200403160-00007 · DOI
  136. Harbarth, 1999, Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 43, 1412, 10.1128/AAC.43.6.1412 · DOI · Paper page
  137. Bode, 2010, Preventing surgical-site infections in nasal carriers of Staphylococcus aureus, N Engl J Med, 362, 9, 10.1056/NEJMoa0808939 · DOI · Paper page
  138. Raz, 1996, A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection, Arch Intern Med, 156, 1109, 10.1001/archinte.1996.00040041109010 · DOI
  139. Ellis, 2007, Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin-resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled trial, Antimicrob Agents Chemother, 51, 3591, 10.1128/AAC.01086-06 · DOI
  140. Diep, 2008, Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men, Ann Intern Med, 148, 249, 10.7326/0003-4819-148-4-200802190-00204 · DOI · Paper page
  141. Patel, 2009, Mupirocin resistance, Clin Infect Dis, 49, 935, 10.1086/605495 · DOI · Paper page
  142. Yang, 2010, Body site colonization in patients with community-associated methicillin-resistant Staphylococcus aureus and other types of S. aureus skin infections, Clin Microbiol Infect, 16, 425, 10.1111/j.1469-0691.2009.02836.x · DOI · Paper page
  143. Kazakova, 2005, A clone of methicillin-resistant Staphylococcus aureus among professional football players, N Engl J Med, 352, 468, 10.1056/NEJMoa042859 · DOI · Paper page
  144. Nguyen, 2005, Recurring methicillin-resistant Staphylococcus aureus infections in a football team, Emerg Infect Dis, 11, 526, 10.3201/eid1104.041094 · DOI · Paper page
  145. Romano, 2006, Outbreak of community-acquired methicillin-resistant Staphylococcus aureus skin infections among a collegiate football team, J Athl Train, 41, 141
  146. Wiese-Posselt, 2007, Successful termination of a furunculosis outbreak due to lukS-lukF-positive, methicillin-susceptible Staphylococcus aureus in a German village by stringent decolonization, 2002-2005, Clin Infect Dis, 44, e88, 10.1086/517503 · DOI
  147. Boubaker, 2004, Panton-valentine leukocidin and staphyloccoccal skin infections in schoolchildren, Emerg Infect Dis, 10, 121, 10.3201/eid1001.030144 · DOI
  148. Whitman, 2010, Chlorhexidine-impregnated cloths to prevent skin and soft-tissue infection in marine recruits: a cluster-randomized, double-blind, controlled effectiveness trial, Infect Control Hosp Epidemiol, 12, 1207, 10.1086/657136 · DOI
  149. American Academy of Pediatrics, Antibacterial Drugs for Newborn Infantsl
  150. Wendt, 2007, Value of whole-body washing with chlorhexidine for the eradication of methicillin-resistant Staphylococcus aureus: a randomized, placebo-controlled, double-blind clinical trial, Infect Control Hosp Epidemiol, 28, 1036, 10.1086/519929 · doi:10.1086/519929
  151. Hurwitz, 1993, Atopic dermatitis, 55
  152. Fisher, 2008, Hypochlorite killing of community-associated methicillin-resistant Staphylococcus aureus, Pediatr Infect Dis J, 27, 934, 10.1097/INF.0b013e318175d871 · DOI
  153. Loeb, 2003, Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization, Cochrane Database Syst Rev, 4
  154. Falagas, 2007, Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials, Am J Infect Control, 35, 106, 10.1016/j.ajic.2006.09.005 · DOI
  155. Washington University School of Medicine, Staphylococcus aureus decolonization study (SuDS) (NCT00731783)
  156. Natividad Medical Center, A prospective trial of nasal mupirocin, hexachlorophene body Wash, systemic antibiotics for prevention of recurrent methicillin resistant staphylococcus aureus infections (NCT01049438)
  157. Los Angeles Biomedical Research Institute, A randomized clinical trial to prevent recurrent CA-MRSA infection (PRIMO) (NCT00560599)
  158. Simor, 2007, Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization, Clin Infect Dis, 44, 178, 10.1086/510392 · DOI · Paper page
  159. Miro, 2005, Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database, Clin Infect Dis, 41, 507, 10.1086/431979 · DOI · Paper page
  160. Levine, 1991, Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis, Ann Intern Med, 115, 674, 10.7326/0003-4819-115-9-674 · DOI · Paper page
  161. Riedel, 2008, Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus, Antimicrob Agents Chemother, 52, 2463, 10.1128/AAC.00300-08 · DOI · Paper page
  162. Cosgrove, 2009, Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic, Clin Infect Dis, 48, 713, 10.1086/597031 · DOI · Paper page
  163. Karchmer, 1983, Rifampin treatment of prosthetic valve endocarditis due to Staphylococcus epidermidis, Rev Infect Dis, 5, S543, 10.1093/clinids/5.Supplement_3.S543 · DOI
  164. Karchmer, 1983, Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy, Ann Intern Med, 98, 447, 10.7326/0003-4819-98-4-447 · DOI · Paper page
  165. Figueroa, 2009, Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program, Clin Infect Dis, 49, 177, 10.1086/600039 · DOI
  166. Benvenuto, 2006, Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers, Antimicrob Agents Chemother, 50, 3245, 10.1128/AAC.00247-06 · DOI · Paper page
  167. Rose, 2007, Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies, J Antimicrob Chemother, 60, 334, 10.1093/jac/dkm170 · DOI
  168. Rose, 2008, Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations, Antimicrob Agents Chemother, 52, 3061, 10.1128/AAC.00102-08 · DOI
  169. Rehm, 2008, Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates, J Antimicrob Chemother, 62, 1413, 10.1093/jac/dkn372 · DOI
  170. Ardura, 2007, Daptomycin therapy for invasive gram-positive bacterial infections in children, Pediatr Infect Dis J, 26, 1128, 10.1097/INF.0b013e31814523f8 · DOI
  171. Chandorkar, 2009, Pharmacokinetics (PK) and safety of 8 and 10 mg/kg of daptomycin in pediatric patients aged 2 to 6 years. [abstract number 1243]
  172. Boucher, 2006, Appropriateness of two-week therapy for catheter-related S. aureus bacteremia [abstract number L-1204]
  173. Jernigan, 1993, Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis, Ann Intern Med, 119, 304, 10.7326/0003-4819-119-4-199308150-00010 · DOI
  174. Cosgrove, 2008, Management of methicillin-resistant Staphylococcus aureus bacteremia, Clin Infect Dis, 46, S386, 10.1086/533595 · DOI
  175. Dworkin, 1989, Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin, Lancet, 2, 1071, 10.1016/S0140-6736(89)91083-0 · DOI · Paper page
  176. Fowler, 1997, Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients, J Am Coll Cardiol, 30, 1072, 10.1016/S0735-1097(97)00250-7 · DOI · Paper page
  177. Sullenberger, 2005, Importance of transesophageal echocardiography in the evaluation of Staphylococcus aureus bacteremia, J Heart Valve Dis, 14, 23
  178. Abraham, 2004, Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S. aureus and methicillin-resistant S. aureus bacteremia, Am Heart J, 147, 536, 10.1016/j.ahj.2003.09.018 · DOI
  179. Valente, 2005, Frequency of infective endocarditis among infants and children with Staphylococcus aureus bacteremia, Pediatrics, 115, e15, 10.1542/peds.2004-1152 · DOI
  180. Fowler, 1998, Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients, Clin Infect Dis, 27, 478, 10.1086/514686 · DOI · Paper page
  181. Chamis, 2001, Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators, Circulation, 104, 1029, 10.1161/hc3401.095097 · DOI · Paper page
  182. Baddour, 2010, Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association, Circulation, 121, 458, 10.1161/CIRCULATIONAHA.109.192665 · DOI · Paper page
  183. Vikram, 2003, Impact of valve surgery on 6-month mortality in adults with complicated, left-sided native valve endocarditis: a propensity analysis, JAMA, 290, 3207, 10.1001/jama.290.24.3207 · DOI · Paper page
  184. D'Agostino, 1985, Valve replacement in patients with native valve endocarditis: what really determines operative outcome?, Ann Thorac Surg, 40, 429, 10.1016/S0003-4975(10)60097-5 · DOI
  185. Mullany, 1989, The surgical treatment of infective endocarditis, World J Surg, 13, 132, 10.1007/BF01671175 · DOI
  186. Bishara, 2001, Long-term outcome of infective endocarditis: the impact of early surgical intervention, Clin Infect Dis, 33, 1636, 10.1086/323785 · DOI
  187. Remadi, 2007, Predictors of death and impact of surgery in Staphylococcus aureus infective endocarditis, Ann Thorac Surg, 83, 1295, 10.1016/j.athoracsur.2006.09.093 · DOI
  188. Lobo, 2010, Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia, Chest, 138, 130, 10.1378/chest.09-1562 · DOI
  189. Combes, 2004, Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia, Am J Respir Crit Care Med, 170, 786, 10.1164/rccm.200403-346OC · DOI
  190. Shorr, 2006, Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy, Crit Care Med, 34, 700, 10.1097/01.CCM.0000201885.57697.21 · DOI
  191. Zahar, 2005, Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia?, Clin Infect Dis, 41, 1224, 10.1086/496923 · DOI
  192. Cruciani, 1996, Penetration of vancomycin into human lung tissue, J Antimicrob Chemother, 38, 865, 10.1093/jac/38.5.865 · DOI · Paper page
  193. Jung, 2010, Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia, Crit Care Med, 38, 175, 10.1097/CCM.0b013e3181b9ecea · DOI
  194. Conte, 2002, Intrapulmonary pharmacokinetics of linezolid, Antimicrob Agents Chemother, 46, 1475, 10.1128/AAC.46.5.1475-1480.2002 · doi:10.1128/aac.46.5.1475-1480.2002
  195. Rubinstein, 2001, Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study, Clin Infect Dis, 32, 402, 10.1086/318486 · DOI · Paper page
  196. Wunderink, 2003, Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia, Clin Ther, 25, 980, 10.1016/S0149-2918(03)80118-2 · DOI · Paper page
  197. Wunderink, 2003, Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia, Chest, 124, 1789, 10.1016/S0012-3692(15)33412-7 · DOI · Paper page
  198. Wunderink, 2008, Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus, Chest, 134, 1200, 10.1378/chest.08-0011 · DOI
  199. Kimura, 1998, Trimethoprim-sulfamethoxazole for the prevention of methicillin-resistant Staphylococcus aureus pneumonia in severely burned patients, J Trauma, 45, 383, 10.1097/00005373-199808000-00032 · doi:10.1097/00005373-199808000-00032
  200. Mathews, 2008, Septic arthritis: current diagnostic and therapeutic algorithm, Curr Opin Rheumatol, 20, 457, 10.1097/BOR.0b013e3283036975 · DOI · Paper page

200 of 349 shown

Cited by

See all 4,191

Metadata

Authors
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., Rybak, M. J., Talan, D. A., & Chambers, H. F.
Venue
Clinical Infectious Diseases
Publisher
Oxford University Press (OUP)
Published
2011-02-01
Volume
52
Issue
3
Pages
e18-e55
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
DOI
10.1093/cid/ciq146
OpenAlex
W2108433768
Cited by
4,191
References
21
FWCI
199.81
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. https://app.cochat.ai/papers/10.1093/cid/ciq146
The paper
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., Rybak, M. J., Talan, D. A., & Chambers, H. F. (2011). Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciq146

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.